Tonix Pharmaceuticals Reports Encouraging Preclinical Immuno-Oncology Data at AACR Meeting

summarizeSummary

Tonix Pharmaceuticals announced positive preclinical data for its TNX-1700 and TNX-4700 immuno-oncology programs at the AACR Annual Meeting, showing promising results in gastric cancer models and favorable pharmacokinetics.

check_boxKey Events

• Positive Preclinical Data for TNX-1700

  An oral presentation highlighted that mTNX-1700, a TFF2-albumin fusion protein, reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged mouse models.

• Favorable Pharmacokinetics for TNX-1700

  A poster presentation showed TNX-1700 exhibited dose-independent, linear pharmacokinetics and extended TFF2 half-life in non-human primates and humanized mice, supporting its potential as a therapeutic candidate.

• Encouraging In Vitro Data for TNX-4700

  Another poster detailed the in vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodies (TNX-4700), demonstrating potent, high-affinity binding and functional antagonism, suggesting opportunities for cancer immunotherapy.

auto_awesomeAnalysis

This filing provides a positive update on Tonix Pharmaceuticals' preclinical immuno-oncology pipeline, which is crucial for a company facing a 'going concern' warning as disclosed in its recent 10-K. The data for TNX-1700, a TFF2-albumin fusion protein, demonstrated its ability to reverse aging-associated gastric inflammation and attenuate tumor progression in preclinical models, along with favorable pharmacokinetics. Additionally, the TNX-4700 program, an anti-BTLA monoclonal antibody, showed potent binding and functional antagonism. While these are early-stage preclinical results, they offer a potential path for value creation and could help attract future investment, providing a much-needed positive signal for the company's long-term viability.